EGFR and chordoma: In 2021, a review article described 14 globally approved EGFR reversible and irreversible inhibitors for anticancer treatment, including gefitinib and erlotinib, some of which may be considered in future studies of combinatorial immunotherapy against chordoma with a special focus on CSCs (42).